Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia

 Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia

Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia

Shots:

  • The companies collaborated to develop liquid biopsy-based CDx based on NGS technology to complement Inovio’s therapies. The collaboration initially focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from VGX-3100
  • QIAGEN’s bioinformatic expertise will raise the predictive biomarker power in Inovio’s patient selection. The assay will now be developed for use on the Illumina NextSeq 550Dx platform
  • VGX-3100 is a late-stage DNA immunotherapy, currently in two P-III trials (REVEAL 1 & 2) and has the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: NBC 7 San Diego

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post